These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24266510)

  • 1. Concepts and Strategies for the Site Specific Delivery of Nanocarrier Based Delivery Systems for Treating Hepatocellular Carcinoma.
    Sharma P; Pandita A; Murthy RS
    Curr Drug Deliv; 2013 Nov; ():. PubMed ID: 24266510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiology, natural history and treatment of hepatocellular carcinoma.
    Colombo M; Sangiovanni A
    Antiviral Res; 2003 Oct; 60(2):145-50. PubMed ID: 14638411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanotechnology Based Approach for Hepatocellular Carcinoma Targeting.
    Alhalmi A; Beg S; Kohli K; Waris M; Singh T
    Curr Drug Targets; 2021; 22(7):779-792. PubMed ID: 33302831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of novel drug delivery system for herbal formulations.
    Ajazuddin ; Saraf S
    Fitoterapia; 2010 Oct; 81(7):680-9. PubMed ID: 20471457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.
    Wu J; Nantz MH; Zern MA
    Front Biosci; 2002 Mar; 7():d717-25. PubMed ID: 11861224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
    Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
    J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
    Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance.
    Rohilla R; Garg T; Goyal AK; Rath G
    Drug Deliv; 2016 Jun; 23(5):1645-61. PubMed ID: 25101832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
    Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
    Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry, pharmacokinetics, pharmacology and recent novel drug delivery systems of paeonol.
    Adki KM; Kulkarni YA
    Life Sci; 2020 Jun; 250():117544. PubMed ID: 32179072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-Albumin/Lactosylated Core-Shell Nanoparticles: Therapy to Treat Hepatocellular Carcinoma for Controlled Delivery of Doxorubicin.
    Teran-Saavedra NG; Sarabia-Sainz JA; Velázquez-Contreras EF; Ramos-Clamont Montfort G; Pedroza-Montero M; Vazquez-Moreno L
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33233564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advancements and Avenues in Nanophytomedicines for Better Pharmacological Responses.
    Saraf S; Gupta A; Alexander A; Khan J; Jangde M; Saraf S
    J Nanosci Nanotechnol; 2015 Jun; 15(6):4070-9. PubMed ID: 26369014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
    Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
    Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
    Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymeric nanoparticles as cancer-specific DNA delivery vectors to human hepatocellular carcinoma.
    Zamboni CG; Kozielski KL; Vaughan HJ; Nakata MM; Kim J; Higgins LJ; Pomper MG; Green JJ
    J Control Release; 2017 Oct; 263():18-28. PubMed ID: 28351668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines: a theranostic approach for hepatocellular carcinoma.
    Usmani A; Mishra A; Ahmad M
    Artif Cells Nanomed Biotechnol; 2018 Jun; 46(4):680-690. PubMed ID: 28884605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
    Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
    Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.